- Home
- CXAI vs PLUR Comparison
CXAI vs PLUR Comparison
Compare CXAI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- PLUR
- Stock Information
- Founded
- CXAI N/A
- PLUR 2001
- Country
- CXAI United States
- PLUR Israel
- Employees
- CXAI N/A
- PLUR N/A
- Industry
- CXAI EDP Services
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CXAI Technology
- PLUR Health Care
- Exchange
- CXAI Nasdaq
- PLUR Nasdaq
- Market Cap
- CXAI 17.8M
- PLUR 36.9M
- IPO Year
- CXAI N/A
- PLUR N/A
- Fundamental
- Price
- CXAI $0.79
- PLUR $4.06
- Analyst Decision
- CXAI
- PLUR Strong Buy
- Analyst Count
- CXAI 0
- PLUR 1
- Target Price
- CXAI N/A
- PLUR $12.00
- AVG Volume (30 Days)
- CXAI 1.1M
- PLUR 9.4K
- Earning Date
- CXAI 11-11-2025
- PLUR 11-11-2025
- Dividend Yield
- CXAI N/A
- PLUR N/A
- EPS Growth
- CXAI N/A
- PLUR N/A
- EPS
- CXAI N/A
- PLUR N/A
- Revenue
- CXAI $6,005,000.00
- PLUR $1,336,000.00
- Revenue This Year
- CXAI N/A
- PLUR $97.38
- Revenue Next Year
- CXAI $60.00
- PLUR $293.97
- P/E Ratio
- CXAI N/A
- PLUR N/A
- Revenue Growth
- CXAI N/A
- PLUR 309.82
- 52 Week Low
- CXAI $0.61
- PLUR $3.33
- 52 Week High
- CXAI $2.54
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- CXAI 49.83
- PLUR 38.61
- Support Level
- CXAI $0.72
- PLUR $4.20
- Resistance Level
- CXAI $0.91
- PLUR $4.35
- Average True Range (ATR)
- CXAI 0.08
- PLUR 0.24
- MACD
- CXAI -0.01
- PLUR -0.02
- Stochastic Oscillator
- CXAI 25.36
- PLUR 28.27
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.